Pindolol, a therapeutic agent used for the treatment of hypertension, antagonistically binds to not only β adrenergic receptors but also to central 5-HT1A receptors [10], and its antagonism for 5-HT1A receptors is assumed to interrupt the autoreceptor-mediated negative feedback. Here, HTR1A is linked to hypertensive disorder.